| Cameron Pharmaceuticals, LLC |
42494042810 |
LORZONE (CHLORZOXAZONE 750 MG) |
2019-11-27 |
832.2500 |
Selling to wholesalers and retailers as a less expensive alternative to the brand, Lorzone. |
None |
2000000 |
None |
None |
None |
None |
None |
None |
Cameron co-developed this product. Novitium Pharma, LLC is the manufacturer and Cameron Pharmaceuticals, LLC is acting as the Distributor. |
None |
| Cameron Pharmaceuticals, LLC |
42494042510 |
LORZONE (CHLORZOXAZONE 375 MG) |
2019-11-27 |
744.2900 |
Selling to wholesalers and retailers as a less expensive alternative to the brand, Lorzone. |
None |
2000000 |
None |
None |
None |
None |
None |
None |
Cameron co-developed this product. Novitium Pharma, LLC is the manufacturer and Cameron Pharmaceuticals, LLC is acting as the Distributor. |
None |
| Celgene |
59572072012 |
INREBIC (fedtratinib) 100mg CAPSULES 120ct |
2019-08-16 |
21000.0000 |
None |
1 |
None |
None |
1 |
2018-02-12 |
1100000000.0000 |
None |
Please see the attached press release for the full deal terms for Celgene's acquisition of Impact Biomedicines. |
No information regarding the volume of patients who may be prescribed this drug is in the public domain or publicly available. INREBIC is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). There are no marketing or pricing plans in the United States or internationally that are in the public domain or publicly available. As with the launch of any new medicine, Celgene actively seeks to educate key stakeholders – including physicians, payers and patients – around the medicine’s indication(s), efficacy, and safety profile. Generating this awareness for INREBIC® will be a critical component of Celgene’s marketing efforts. Additionally, as with all of its products, Celgene determined the price of INREBIC® with strong consideration of its benefit to patients, health systems and society and in accordance with Celgene’s publicized Pricing Principles that focus on access, value, innovation and flexibility. |
https://oshpd.ca.gov/ml/v1/resources/document?rs:path=/Data-And-Reports/Documents/Topics/Cost-Transparency/Rx/Q3-New-Drug-Public-Release-Supporting-Documents/Celgene-Acquisition-of-Impact-Biomedicines_Press-Release.pdf |
| Celgene |
59572071101 |
REBLOZYL (luspatercept-aamt) 25 mg powder for solution for injection |
2019-11-08 |
3441.1800 |
None |
1 |
None |
None |
1 |
2011-08-02 |
25000000.0000 |
None |
In 2011, Celgene made an upfront payment to Acceleron of $25 million as part of a joint development and commercialization agreement for Reblozyl. Under this agreement, Acceleron is eligible to receive up to $217 million if specific development, regulatory and commercial milestones are reached for REBLOZYL. |
No information regarding the volume of patients who may be prescribed this drug is in the public domain or publicly available. REBLOZYL® is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. There are no marketing or pricing plans in the United States or internationally that are in the public domain or publicly available. As with the launch of any new medicine, Celgene actively seeks to educate key stakeholders – including physicians, payers and patients – around the medicine’s indication(s), efficacy, and safety profile. Generating this awareness for REBLOZYL® will be a critical component of Celgene’s marketing efforts. Additionally, as with all of its products, Celgene determined the price of REBLOZYL® with strong consideration of its benefit to patients, health systems and society and in accordance with Celgene’s publicized Pricing Principles that focus on access, value, innovation and flexibility. |
None |
| Celgene |
59572077501 |
REBLOZYL (luspatercept-aamt) 75 mg powder for solution for injection |
2019-11-08 |
10323.5300 |
None |
1 |
None |
None |
1 |
2011-08-02 |
25000000.0000 |
None |
In 2011, Celgene made an upfront payment to Acceleron of $25 million as part of a joint development and commercialization agreement for Reblozyl. Under this agreement, Acceleron is eligible to receive up to $217 million if specific development, regulatory and commercial milestones are reached for REBLOZYL. |
No information regarding the volume of patients who may be prescribed this drug is in the public domain or publicly available. REBLOZYL® is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. There are no marketing or pricing plans in the United States or internationally that are in the public domain or publicly available. As with the launch of any new medicine, Celgene actively seeks to educate key stakeholders – including physicians, payers and patients – around the medicine’s indication(s), efficacy, and safety profile. Generating this awareness for REBLOZYL® will be a critical component of Celgene’s marketing efforts. Additionally, as with all of its products, Celgene determined the price of REBLOZYL® with strong consideration of its benefit to patients, health systems and society and in accordance with Celgene’s publicized Pricing Principles that focus on access, value, innovation and flexibility. |
None |
| Circassia Pharmaceuticals |
72124000101 |
Inhalation Powder |
2019-10-17 |
995.0000 |
Marketing to support the launch of Duaklir will focus on educating HCPs and patients on the approved indication as well as safety information, all included within the FDA approved label. This education will occur in the form of: the Duaklir website, interactive core visual aids, banner ads, email promotions and HCP and patient leave-behind materials. Pricing is evaluated by Circassia's Pricing Committee and approved by its Board of Directors. |
None |
15000000 |
None |
None |
2019-06-17 |
218840450.0000 |
None |
The acquisition price amount entered reflects the price of a combination portfolio acquisition which includes future royalties based on estimated sales. |
None |
None |
| Celltrion USA, Inc. |
72606000201 |
Temixys (lamivudine and tenofovir disoproxil fumarate |
2019-09-03 |
850.0000 |
Celltrion USA is a new pharmaceutical company and has not yet begun direct-to-consumer marketing activities. We will be working towards increasing awareness of the availability of a new branded generic product to healthcare providers (HCPs) through speaker engagements and seminars, and provide FDA approved medication information through print material, mobile application, and website. A copay card will be offered to eligible commercially-insured patients. |
None |
3000 |
None |
None |
None |
None |
None |
None |
The acquisition-related fields blank was because Celltrion developed the drug. The first sale of Temixys was made on 9/30/2019, and it was a direct sale to an independent pharmacy. This product is currently not offered through the wholesalers, because Celltrion is negotiating the distribution service agreements. Our Trade Contracts Team is confident that the negotiations will wrap up in the next week or two. Temixys needed to be uploaded onto Medispan because some of the wholesalers that Celltrion intends to contract with informed us that they needed to see the information on that database before moving forward with negotiations. At the time of the compendia submissions, Celltrion had believed that since our product was available for direct sale, indicating 9/3/2019 as the effective date would not be of an issue. |
None |
| Coherus BioSciences, Inc. |
70114010101 |
UDENYCA (pegfilgrastim-cbqv) 6mg/.06mL solution in a single-dose prefilled syringe |
2019-01-03 |
4175.0000 |
While specific marketing & pricing plans are not available in the public domain, generally Coherus plans to market UDENYCA (pegfilgrastim-cbqv) in the US as a high quality, lower cost biosimilar option to the referenced biologic, Neulasta (pegfilgrastim). As of 2019, Coherus offers UDENYCA at 32% discount off the WAC price of Neulasta. Coherus seeks to deliver choice-without-compromise by delivering the high-quality treatment & outcomes patients and providers expect, while reducing overall costs for patients, providers and the healthcare system. |
None |
11000 |
None |
None |
None |
None |
None |
None |
The drug UDENYCA (pegfilgrastim-cbqv) was not acquired. |
None |